Targeting these timing with drug delivery minimize side effect and maximize effectiveness, in type 2 diabetes Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors administered at night induced improved glucose control [134]. Here, SLC5A2 is linked to type 2 diabetes mellitus.